Mobile

A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Peptide Vaccine Monotherapy in HLA-A*0201-Positive Pat...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-005059-32

A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Peptide Vaccine Monotherapy in HLA-A*0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine the safety and efficacy, measured as best objective response rate (BORR), of MDX-010 when administered in combination with a gp100 melanoma peptide vaccine and to demonstrate the independent contributions of the vaccine and MDX-010 when given to patients with unresectable Stage III or IV melanoma who have been previously treated with other agents.

Critère d'inclusion

  • HLA-A*0201-Positive Patients with Previously Treated, Unresectable Stage III or IV Melanoma

Liens